Immune-Based Combinations for Metastatic Triple Negative Breast Cancer in Clinical Trials: Current Knowledge and Therapeutic Prospects

Clinical trials suggest that immune checkpoint inhibitor (ICI) monotherapy could be beneficial in a subset of mTNBC patients, and several immune-based combinations have reported notable results in recently presented or published studies. Some of these combination strategies have been approved for mTNBC, as in the case of chemoimmunotherapy in PD-L1 positive patients. Numerous trials are investigating novel ICI-based combinations.